UNASSIGNED: Atherogenesis is associated with the early retention of low-density lipoproteins (LDL) in the arterial intima by interaction with glycosaminoglycan (GAG)-side chains of proteoglycans. Retained LDL undergo reactive @entity26 species-mediated oxidation. Oxidized LDL trigger @entity66 ( @entity66 ) and @entity32 , contributing to @entity731 development. Recently, we reported the preventive anti-atherogenic properties of the chimeric mouse/human monoclonal antibody (mAb) @entity61448 R99-LALA, which were related to the induction of anti-chondroitin @entity597 antibody response able to inhibit chondroitin sulfate dependent LDL-enhanced oxidation. In the present work, we aimed at further investigating the impact of @entity61448 R99-LALA mAb vaccination on progressive @entity731 in @entity6970 -deficient @entity19 ( @entity6970 (-/-)) fed with a high-fat high- @entity165 diet receiving 5 doses (50  g) of the antibody subcutaneously, when ~5% of the aortic area was covered by lesions. Therapeutic immunization with @entity61448 R99-LALA mAb halted @entity731 lesions progression. In addition, aortic @entity66 was modulated, as shown by a significant (p<0.05) reduction of lipid and protein oxidation, preservation of antioxidant enzymes activity and reduced @entity2041 , together with a decrease of @entity842 levels. @entity61448 R99-LALA mAb immunization also regulated aortic NF-kB activation, diminishing the proinflammatory IL1-b and TNF-a gene expression as well as the infiltration of macrophages into the arterial wall. The therapeutic immunization of @entity6970 (-/-) with progressive @entity1856 and persistent @entity1007 using @entity61448 R99-LALA mAb arrested further development of lesions, accompanied by a decrease of aortic @entity66 and NF-kB-regulated pro-inflammatory cytokine gene expression. These results contribute to broaden the potential use of this anti-GAG antibody-based immunotherapy as a novel approach to target @entity731 at different phases of progression.

Arresting progressive @entity731 by immunization with an anti-glycosaminoglycan monoclonal antibody in XXXX -deficient @entity19 .

@entity32 :: ('MESH:D007249', 'Disease') :: ['inflammation'] @entity6970 :: ('11816(Tax:10090)', 'Gene') :: ['apolipoprotein E', 'apoE'] @entity66 :: ('MESH:D004194', 'Disease') :: ['OS', 'oxidative stress'] @entity1007 :: ('MESH:D006937', 'Disease') :: ['hypercholesterolemia'] @entity19 :: ('10090', 'Species') :: ['mice'] @entity26 :: ('MESH:D010100', 'Chemical') :: ['oxygen'] @entity2041 :: ('MESH:D005978', 'Chemical') :: ['glutathione'] @entity61448 :: ('105154', 'Species') :: ['chP3'] @entity842 :: ('MESH:D009569', 'Chemical') :: ['nitric oxide'] @entity1856 :: ('MESH:D058226', 'Disease') :: ['atheromas'] @entity731 :: ('MESH:D050197', 'Disease') :: ['atherosclerotic', 'atherosclerosis'] @entity165 :: ('MESH:D002784', 'Chemical') :: ['cholesterol'] @entity597 :: ('CHEBI:16189', 'Chemical') :: ['sulfate']
@entity6970 :: (11816(Tax:10090),Gene) :: ['apolipoprotein E']
